Director/PDMR Shareholding

Hikma Pharmaceuticals Plc
09 May 2024
 

Hikma Pharmaceuticals PLC

(the "Company")

 

LONDON, 9 May 2024: Hikma Pharmaceuticals PLC (LSE: HIK) (NasdaqDubai: HIK) (LEI: 549300BNS685UXH4JI75) announces that the below listed Persons Discharging Managerial Responsibility ("PDMRs") of the Company acquired Ordinary Shares in the Company, which were purchased under a dividend reinvestment plan ("DRIP").

This notification is made under Article 19(1) of the EU Market Abuse Regulation 596/2014 as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018 ("MAR"). The information set out below is provided in accordance with the requirements of Article 19(3) of MAR.

Notification and public disclosure of transactions by persons discharging managerial responsibilities

Riad Mishlawi

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Riad Mishlawi

2

Reason for the notification

a)

Position/status

Chief Executive Officer

b)

Initial notification /Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Hikma Pharmaceuticals PLC

b)

LEI

549300BNS685UXH4JI75

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument and identification code

Description: Ordinary shares of 10 pence each (Shares)

ID Code: GB00B0LCW083

b)

Nature of the transaction

 

Acquisition of Ordinary Shares through participation in a DRIP.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£19.79

736

d)

Aggregated information

Price(s): £19.79

Volume(s): 736

Total: £14,564.29

e)

Date of the transaction

7 May 2024

f)

Place of the transaction

London Stock Exchange (XLON)

Susan Ringdal

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Susan Ringdal

2

Reason for the notification

a)

Position/status

PDMR

b)

Initial notification /Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Hikma Pharmaceuticals PLC

b)

LEI

549300BNS685UXH4JI75

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument and identification code

Description: Ordinary shares of 10 pence each (Shares)

ID Code: GB00B0LCW083

b)

Nature of the transaction

 

Acquisition of Ordinary Shares through participation in a DRIP.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£19.79

180

d)

Aggregated information

Price(s): £19.79

Volume(s): 180

Total: £3,561.92

e)

Date of the transaction

7 May 2024

f)

Place of the transaction

London Stock Exchange (XLON)

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument and identification code

Description: Ordinary shares of 10 pence each (Shares)

ID Code: GB00B0LCW083

b)

Nature of the transaction

 

Acquisition of Ordinary Shares through participation in a DRIP.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£19.34

726

d)

Aggregated information

Price(s): £19.34

Volume(s): 726

Total: £14,040.84

e)

Date of the transaction

3 May 2024

f)

Place of the transaction

London Stock Exchange (XLON)

Hussein Arkhagha

 1

 Details of the person discharging managerial responsibilities / person   closely associated

 a)

 Name

 Hussein Arkhagha

 2

 Reason for the notification

 a)

 Position/status

 PDMR

 b)

Initial notification   /Amendment

 Initial notification

 3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 a)

 Name

 Hikma Pharmaceuticals PLC

 b)

 LEI

 549300BNS685UXH4JI75

 4

   Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 a)

Description of the financial instrument, type of instrument and identification code

 Description: Ordinary shares of 10 pence each (Shares)

 ID Code: GB00B0LCW083

 b)

Nature of the transaction

 

 Acquisition of Ordinary Shares through participation in a DRIP.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£19.79

297

d)

Aggregated information

Price(s): £19.79

Volume(s): 297

Total: £5,877.17

e)

Date of the transaction

7 May 2024

f)

Place of the transaction

London Stock Exchange (XLON)

4

   Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 a)

Description of the financial instrument, type of instrument and identification code

 Description: Ordinary shares of 10 pence each (Shares)

 ID Code: GB00B0LCW083

 b)

Nature of the transaction

 

 Acquisition of Ordinary Shares through participation in a DRIP.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£19.34

150

d)

Aggregated information

Price(s): £19.34

Volume(s): 150

Total: £2,901.00

e)

Date of the transaction

3 May 2024

f)

Place of the transaction

London Stock Exchange (XLON)

Julie Hill

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Julie Hill

2

Reason for the notification

a)

Position/status

PDMR

b)

Initial notification /Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Hikma Pharmaceuticals PLC

b)

LEI

549300BNS685UXH4JI75

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument and identification code

Description: Ordinary shares of 10 pence each (Shares)

ID Code: GB00B0LCW083

b)

Nature of the transaction

 

Acquisition of Ordinary Shares through participation in a DRIP.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£19.79

59

d)

Aggregated information

Price(s): £19.79

Volume(s): 59

Total: £1,167.52

e)

Date of the transaction

7 May 2024

f)

Place of the transaction

London Stock Exchange (XLON)

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument and identification code

Description: Ordinary shares of 10 pence each (Shares)

ID Code: GB00B0LCW083

b)

Nature of the transaction

 

Acquisition of Ordinary Shares through participation in a DRIP.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£19.34

1

d)

Aggregated information

Price(s): £19.34

Volume(s): 1

Total: £19.34

e)

Date of the transaction

3 May 2024

f)

Place of the transaction

London Stock Exchange (XLON)

 

 

Helen Middlemist

Group Company Secretary
+44 (0) 20 7399 2760

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UK 100

Latest directors dealings